Period description | Screening | Placebo run-in | Treatment period 1 | Treatment period 2 | Follow-upf | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day (relative to Day 1) | -45 to-1 days | 1 | 2–12 | 13 | 14 | 15 | 16–26 | 27 | 28 | 29 | 30–40 | 41 | 42 | 43 | 44 | 45–55 | 56 |
Admission to Unit | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â | Â |
Discharge | Â | Â | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â |
Outpatient visit | X | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
Screening assessmentsa | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Brief Physical | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
12-lead ECGb | X | X | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X |
Vital signs | X | X | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X |
Urine drug/alcohol screen | X | X | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â | X |
β-hcg (women) | X | X |  | X |  |  |  | X |  |  |  | X |  |  |  |  | X |
standard blood tests and urinalysis | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X |
Randomisation | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Study treatment dosing | Â | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | Â |
Concomitant medication review | Â | X | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â | X |
Meal served | Â | Â | Â | X | X | X | Â | X | X | X | Â | X | X | X | Â | Â | Â |
Blood samplesc | Â | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â |
Metabonomics (Stool and urine) | Â | Â | Â | <--------------------> | Â | <--------------------> | Â | <-----------------> | Â | Â | Â | ||||||
Microbiomics (Stool) | Â | Â | Â | <--------------------> | Â | <--------------------> | Â | <-----------------> | Â | Â | Â | ||||||
PBC-40 questionnaired | Â | X | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â | X |
GSRSd | Â | X | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â | X |
5-D Itch scaled | Â | X | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | Â | X |
Faecal Occult blood | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X | Â | Â | Â | X |
Pruritus 0–10 point scale (electronic diary)e |  | <---------------------------------------------------------------------> | |||||||||||||||
AE assessment | Â | <---------------------------------------------------------------------> | |||||||||||||||
PGx | For subjects who consent only. Collect one PGx sample after the start of dosing, preferably on day 1 | ||||||||||||||||
Exit interview | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |